Market Overview

56th Annual Symposium of the SSIEM: APR Will Introduce Its Innovative Phe-Free Medical Food for PKU Management Together with New Original Scientific Data

Share:

APR Applied Pharma Research sa ("APR"), the Swiss independent developer
of science driven and patent protected healthcare products, is proud to
announce it will take part to the forthcoming Annual Symposium of the
SSIEM (Society for the Study of Inborn Errors of Metabolism), which will
be held in Athens on September 4th-7th.

This international congress, attended by academic leaders, clinicians
and research scientists from leading Universities and Institutes, will
be the showcase for presenting officially the company innovative
Phenylalanine (Phe)-free medical food for Phenylketonuria (PKU) dietary
management
, powered by APR patented Physiomimic™ Technology.

In the occasion of the congress, APR will sponsor the satellite
symposium "Physiological Absorption of amino acids: rationale and
expected benefits" (Thursday 6th Sept from 7.30 to 8.30 am – Mitropoulos
Hall), where international experts in PKU will share and discuss the projected
benefits
for PKU patients of a medical food providing a prolonged
release of amino acids (AA)
allowing an efficient utilization of
AAs
.

The Satellite Symposium, chaired by Prof. Francjan Van Spronsen and
Prof. Alberto Burlina and involving Prof. Rani Singh, Dr. Julio César
Rocha, Prof. Anita Mac Donald, will offer the opportunity to learn about
the distinctive features of APR Phe-free medical food for PKU
management and the patented technology behind it – Phyisiomimic™
Technology, whilst being introduced to scientific data
(preclinical and kinetics in human subjects) underpinning the company
innovation
.

In addition, during the congress, new pre-clinical data
supporting the potential of APR's innovative AA formulation to modulate
the trend of some metabolic markers in the same direction as dietary
proteins ("Preliminary indications of metabolic modulation by provision
of amino acids engineered to allow physiological absorption") will be
presented in a poster.

As confirmed by a recent international market research, management of
PKU still represents a challenge for clinicians, patients and families

who depend to varying degrees on a restricted long-life dietary regimen
and AA supplementations. Innovative solutions that improve the
efficiency of AA utilization and control better the Phe levels
fluctuations, while maintaining normal energy intake, are a real
existing need.

APR Phe-free Medical Food, powered by the patented Physiomimic™
Technology, has been specifically engineered to allow a physiological
absorption of amino acids, mimicking that of dietary proteins
. Its
advanced formulation has the potential to contribute to
the maintenance of PHE levels within the recommended ranges
, with
less prominent fluctuations of PHE levels over time, thus meeting one of
the most significant healthcare professionals' concerns. The applied
patented technology, on the other hand, is able to mask taste and
odor of free amino acids
, by creating a product that can be easily
accepted by patients in order to obtain a better and lasting
compliance to the dietary treatment
.

"We are extremely pleased to have the honor to take part to this
important event and to offer to patients and healthcare professionals a
new option for PKU management, which marks an important milestone for
our company: being a player in the inherited metabolic diseases arena.

" said Giorgio Reiner, Corporate Director R&D of APR "Starting
from PKU unmet clinical and nutritional needs, we leveraged our
extensive know-how in pharmaceutical technologies to develop a Medical
Food which aims at delivering significant and tangible benefits for a
better quality of life."

Throughout the lifetime of the event, APR will be available at its booth
in the Exhibition Area, where it will be possible to get to know the
company innovation, gather information and interview the company staff.

About Phenylketonuria or PKU

Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder
affecting about 50.000 people worldwide. PKU is characterized by the
deficiency or the malfunctioning of a liver enzyme needed to process
phenylalanine ("Phe"), an essential amino acid found in most
protein-containing food. Excessive amounts of Phe in the bloodstream
become toxic to the brain, impairing the normal development of the
central nervous system. If not properly treated, PKU leads to severe,
non-recoverable mental retardation and major cognitive disabilities. PKU
can only be treated through a strict, life-long, low-protein (low-Phe)
dietetic treatment combined with a daily assumption of low-protein
modified foods and medical food, which provides Phe-free amino acids and
other important nutrients, needed due to the dietary restrictions of PKU
patients.

About APR Applied Pharma Research s.a.

APR is a Swiss, independent developer of science driven, patent
protected healthcare products. The Company identifies, develops and
licenses, value added products designed to address patient or consumer
needs in niche or rare therapeutic areas on a global basis. In
particular, APR's business model is currently focused on two pillars:
(i) internally developed and financed (alone or together with
co-development partners) proprietary, value added products to be
licensed to healthcare companies for their commercialization, and (ii)
support to third party projects by offering added value R&D services
under contract and fee for service arrangements. APR has a balanced
pipeline of revenue generating branded products marketed in all major
markets, combined with a compelling pipeline of products at different
stages of development. APR has entered into licensing and partnership
agreements with pharmaceutical companies in over 70 countries, with
international sales on a worldwide basis.

For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharmaproducts/medical-prescription/genetic-metabolic-disease/

View Comments and Join the Discussion!